Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.
Hepatologist Tim Jobson, co-founder of Predictive Health Intelligence, joins Louise Campbell and Roger Green to provide an update on PHI’s work and discuss implications for databases, patient recruitment and special population issues.
This week’s vault exercise looks back to our coverage of The EASL Congress 2023, when the panel discusses the role of FIB-4 and other elements in the clinical care pathway.
Hannes Hagstrom and the Surfers consider how the need for predictive biomarkers will co-evolve with in-office screening as multiple drugs come to market.
Hannes Hagstrom joins the Surfers to explore the ways that increased access to and awareness of VCTE or other in-office scanning will improve MASLD therapy.
Hannes Hagstrom join the Surfers in discussing studies that demonstrate the value of different nutritional approaches in driving improved liver health.
Hannes Hagstrom joins the Surfers to discuss recent studies focused on VCTE. , both in its prognostic capability for MASLD patients when compared to biopsy and separately as a therapeutic agent.
Hannes Hagstrom joins the Surfers to discuss the value of VCTE or other in-office MASLD monitoring due to the results providing prognoses comparable or superior to biopsy and feedback for patient self-management.
Fatty Liver Alliance Founder Mike Betel joins Roger Green to consider how patient incentives to participate in MASH clinical trials might need to change now that prescribers have an approved drug for treating MASH patients.
MASLD patient advocates consider new needs and opportunities for other stakeholders after the Rezdiffra approval and launch.
